Robotic firm's stellar listing will test appetite for humanoids, and whether the A-share market can expand its investor base; Alibaba's $10.2bn equity raise will fuel its AI ambitions.

One of the investors in the undisclosed licencing deal is fast-growing Chinese tea firm Ningji.

The DRAM manufacturer raised Rmb57.9bn ($8.6bn) in Asia’s largest IPO of 2026 so far and has become China’s largest onshore-listed company by market value, raising questions over the chip maker's valuation and growth prospects.

Industrial activity remained a “consistent bright spot" throughout 2025 amid 5% GDP growth; there are consistent deflationary pressures.

The US pharmaceutical giant will pay $650m upfront to support 12 cancer medicine programmes with HKEX-listed Innovent; the collaboration includes co-commercialisation rights in the US and Europe.

Proceeds from the one-year zero coupon guaranteed bonds will be used to support the non-ferrous metal company’s overseas business.

Hong Kong's finance secretary Paul Chan said the deal will "attract more cross-boundary Rmb financing and trading activities to Hong Kong".

Three brokers, including Hong Kong’s largest online brokerage Futu, have been heavily penalised by Chinese regulators, in an effort to clean up market misconduct and to curb illegal outflows.

Rather than relying solely on exports, Chinese companies are gradually integrating into Europe’s industrial fabric, argues Collabrium Partners' Adam Zhang Yu.